Skip to main content

Year: 2025

Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate

Evaxion introduces EVX-04, a novel vaccine candidate targeting multiple non-conventional ERV tumor antigens, developed with our AI-Immunology™ platform EVX-04 is a therapeutic cancer vaccine candidate designed for acute myeloid leukemia New data showing EVX-04 induces strong T-cell responses and cancer cell killing will be presented at an oral session at the American Society of Hematology (ASH) Annual Meeting and Exposition in Florida on December 6, 2025 The concept behind EVX-04 is broadly applicable with potential across cancers where immunotherapies remain inadequateCOPENHAGEN, Denmark, November 3, 2025 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, expands its R&D pipeline with the addition EVX-04, an AI-designed precision...

Continue reading

SAGA Metals Provides Update on Double Mer Uranium Project: A Well-Positioned Asset in North America as the Uranium Boom Accelerates

VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) — SAGA Metals Corp. (“SAGA” or the “Company”) (TSXV: SAGA) (OTCQB: SAGMF) (FSE: 20H), a North American exploration company advancing critical mineral discoveries, is strategically positioned to capitalize on the explosive growth in the uranium sector as global nuclear commitments and artificial intelligence (AI) infrastructure propel demand far beyond current supply horizons. SAGA’s Double Mer Uranium Project: Large-Tonnage Potential in Labrador Amid this uranium fervor, SAGA Metals is well-positioned with its high potential Double Mer Uranium Project in Labrador, Canada—a drill-ready asset primed to contribute to North America’s critical minerals security. Located 90 km northeast of Happy Valley-Goose Bay near the prolific Central Mineral Belt (CMB), the 100%-owned project...

Continue reading

Roche to present new data from its broad and innovative haematology portfolio at ASH 2025

Findings further demonstrate the effectiveness of Roche’s approved medicines in advancing treatment standards for people with blood disorders Data from innovative pipeline signals progress toward improved outcomes in haemophilia A, lymphoma, and multiple myeloma Basel, 3 November 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will showcase 46 abstracts, including 12 oral presentations, from its industry-leading haematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, held 6-9 December 2025 in Orlando, Florida, US. “The data we will present at this year’s ASH meeting underscore our commitment to driving innovation across haematology and reflect meaningful progress towards improved treatment of multiple blood disorders,” said Levi Garraway, MD, PhD, Roche’s Chief...

Continue reading

SalMar – Invitation to presentation of the third quarter 2025 results

SalMar presents results for the third quarter 2025 on Thursday 6 November 2025 at 08:00 CET. The presentation will be held at Grand Hotel in Oslo. Please note that the presentation will be held at Grand Hotel in Oslo, Karl Johans gate 31, and not at Hotel Continental as in previous quarterly presentations. CEO Frode Arntsen and CFO Ulrik Steinvik will be representing the company. The presentation will in addition be available on Norwegian webcast at 08:00 CET on www.salmar.no. There will be opportunity to send in questions during the Norwegian presentation. An English webcast (recording) will be available from 10:00 CET on www.salmar.no. After the presentation two group presentations will be arranged, one physical presentation in Norwegian at 12:00 CET and one digital presentation in English at 15:15 CET. For registration and dial in details,...

Continue reading

IRADIMED CORPORATION Reports Record Third Quarter 2025 Financial Results

Announces Regular Quarterly Cash Dividend of $0.17 Per Share and Raises Full-Year GuidanceReports record revenue of $21.2 million for the third quarter of 2025, an increase of $2.9 million, or 16%, compared to the same period in 2024. Reports record GAAP diluted EPS of $0.43 and non-GAAP diluted EPS of $0.47 for the third quarter of 2025, which are increases of 8% and 9%, respectively, compared to the same period in 2024. Raises full-year guidance to revenue of $82.5 million to $83.5 million and GAAP diluted EPS to $1.68 to $1.72. Declares a regular quarterly cash dividend of $0.17 per share of common stock for the fourth quarter of 2025, payable on November 25, 2025.ORLANDO, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) — IRADIMED CORPORATION (the “Company” or “Iradimed”) (NASDAQ: IRMD) announced today its financial results for the...

Continue reading

Shell plc Commences Any and All Exchange Offers for Six Series of USD Notes Issued by Shell International Finance B.V. and BG Energy Capital plc

Press Release November 3, 2025 Shell plc Commences Any and All ExchangeOffers for Six Series of USD Notes Issued by Shell International Finance B.V. and BG Energy Capital plc Shell plc (“Shell”) (LSE: SHEL) (NYSE: SHEL) (AEX: SHELL) today announces the commencement of offers to Eligible Holders (as defined below) to exchange (the “Exchange Offers” and each, an “Exchange Offer”) any and all validly tendered (and not validly withdrawn) and accepted notes of five series of notes issued by Shell International Finance B.V. (“Shell International Finance”) (such notes, the “Shell International Finance Notes”) and one series of notes issued by BG Energy Capital plc (“BGEC”) (such notes, the “BGEC Notes” and such BGEC Notes, together with the Shell International Finance Notes, the “Old Notes”) for a combination of cash and a corresponding series...

Continue reading

SUTNTIB AB Tewox publishes its NAV for October 2025

Vilnius, Lithuania, Nov. 03, 2025 (GLOBE NEWSWIRE) — As at the end of October 2025, the net asset value (NAV) of SUTNTIB AB Tewox decreased to EUR 44,897,707, compared to the previously determined NAV of EUR 45,276,142 at the end of September 2025. The share price decreased to EUR 1.0725, from EUR 1.0815 at the end of September 2025. The pro-forma internal rate of return (IRR) decreased to 3.09%, compared to previously announced IRR of 3.41% at the end of September 2025. Contact person for further information: Paulius Nevinskas Manager of the Investment Company paulius.nevinskas@lordslb.lt https://lordslb.lt/tewox_bonds/

Continue reading

Datavault AI Announces Record Date of Nov. 14, 2025, for Dream Bowl Draft Meme Coin Distribution to All Eligible Scilex and Datavault AI Shareholders

Exclusive Distribution Commemorates First AI-Generated Data-Driven Draft Coin for both College Football and E-Sports Live Jan. 11, 2026, from AT&T Stadium in Dallas, Texas PHILADELPHIA, Nov. 03, 2025 (GLOBE NEWSWIRE) — via IBN — Datavault AI Inc. (Nasdaq: DVLT), a pioneer in AI-powered data valuation and tokenization, today unveiled plans for the highly anticipated Dream Bowl Draft, set to select top invitees for the Crusaders vs. Patriots matchup in the 2026 Dream Bowl presented by Scilex (Nasdaq: SCLX). This marquee event will culminate on Jan. 11, 2026, at AT&T Stadium in Dallas, Texas, where elite athletes will compete for the Dream Bowl Championship. Building on this excitement, Datavault AI will also host the professional Drone Racing and e-sports Championships, crowning the World Champion of Madden Football...

Continue reading

Worksport ($WKSP) to Showcase SOLIS™ and COR™ at SEMA 2025, Expanding Global Distribution Opportunities

Company to Meet Dealers, Distributors and Showcase Industry-Defining Clean-Tech Solutions — SOLIS Solar Tonneau and COR Portable Energy System — in SEMA’s “New Product” Evaluation Category West Seneca, New York, Nov. 03, 2025 (GLOBE NEWSWIRE) — Worksport Ltd. (NASDAQ: WKSP) (“Worksport” or the “Company”), a U.S.-based innovator in advanced manufacturing and distributed clean energy technologies, serving both consumer and industrial markets, today announced that it will be exhibiting at the 2025 SEMA Show in Las Vegas, Nevada (November 4–7) — one of the world’s premier automotive trade events — where the Company will showcase its product portfolio including its upcoming flagship clean-energy innovations: the SOLIS Solar Tonneau Cover and COR Portable Energy System. Both products will be featured in SEMA’s “New Product” category...

Continue reading

SurgePays to Host Third Quarter 2025 Earnings Conference Call

BARTLETT, Tenn., Nov. 03, 2025 (GLOBE NEWSWIRE) — SurgePays, Inc. (NASDAQ: SURG)(“SurgePays” or the “Company”), a wireless and fintech technology company connecting underserved consumers to essential mobile and financial services, today announced that it plans to host a conference call and report its financial results for the third quarter ended September 30, 2025, on Wednesday, November 12, 2025. Event: SurgePays Third Quarter 2025 Financial Results Conference CallDate: Wednesday, November 12, 2025Time: 5:00 p.m. E.T.Dial-in Number: 1-888-506-0062Access Code: 350444Webcast: https://ir.surgepays.com/company-events The webcast replay will remain available until 12:00 a.m. E.T. on Thursday, November 12, 2026. About SurgePays, Inc.SurgePays, Inc. (NASDAQ: SURG) is a wireless, fintech, and point-of-sale technology...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.